Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.
You may also be interested in...
Arena Optimistic About Lorcaserin But Analysts More Reserved
Arena Pharmaceuticals argues it has the necessary safety data to convince an FDA advisory committee to recommend approval of its key drug, a weight loss treatment.
Arena Optimistic About Lorcaserin But Analysts More Reserved
Arena Pharmaceuticals argues it has the necessary safety data to convince an FDA advisory committee to recommend approval of its key drug, a weight loss treatment.
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January